Literature DB >> 22350489

A review on various targeted anticancer therapies.

Junjie Li1, Feng Chen, Marlein Miranda Cona, Yuanbo Feng, Uwe Himmelreich, Raymond Oyen, Alfons Verbruggen, Yicheng Ni.   

Abstract

Translational oncology aims to translate laboratory research into new anticancer therapies. Contrary to conventional surgery, chemotherapy, and radiotherapy, targeted anticancer therapy (TAT) refers to systemic administration of drugs with particular mechanisms that specifically act on well-defined targets or biologic pathways that, when activated or inactivated, may cause regression or destruction of the malignant process, meanwhile with minimized adverse effects on healthy tissues. In this article, we intend to first give a brief review on various known TAT approaches that are deemed promising for clinical applications in the current trend of personalized medicine, and then we will introduce our newly developed approach namely small molecular sequential dual targeting theragnostic strategy as a generalized class of TAT for the management of most solid malignancies, which, after optimization, is expected to help improve overall cancer treatability and curability.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350489     DOI: 10.1007/s11523-012-0212-2

Source DB:  PubMed          Journal:  Target Oncol        ISSN: 1776-2596            Impact factor:   4.493


  106 in total

1.  Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists.

Authors:  Niklaus G Schaefer; Jiemin Ma; Peng Huang; Judy Buchanan; Richard L Wahl
Journal:  J Nucl Med       Date:  2010-05-19       Impact factor: 10.057

2.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Authors:  Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

Review 3.  Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy.

Authors:  Qi Zhang; Guihua Chen; Xinyuan Liu; Qijun Qian
Journal:  Cell Res       Date:  2007-02       Impact factor: 25.617

4.  Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging.

Authors:  Y Ni; C Pislaru; H Bosmans; S Pislaru; Y Miao; J Bogaert; S Dymarkowski; J Yu; W Semmler; F Van de Werf; A L Baert; G Marchal
Journal:  Eur Radiol       Date:  2001       Impact factor: 5.315

Review 5.  Targeted therapies for cancer 2004.

Authors:  Jeffrey S Ross; David P Schenkein; Robert Pietrusko; Mark Rolfe; Gerald P Linette; James Stec; Nancy E Stagliano; Geoffrey S Ginsburg; W Fraser Symmans; Lajos Pusztai; Gabriel N Hortobagyi
Journal:  Am J Clin Pathol       Date:  2004-10       Impact factor: 2.493

Review 6.  Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer.

Authors:  S M Okarvi
Journal:  Cancer Treat Rev       Date:  2007-09-17       Impact factor: 12.111

7.  Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.

Authors:  Philipp le Coutre; Karl-Anton Kreuzer; Stefan Pursche; Malte v Bonin; Traugott Leopold; Gökben Baskaynak; Bernd Dörken; Gerhard Ehninger; Oliver Ottmann; Andreas Jenke; Martin Bornhäuser; Eberhard Schleyer
Journal:  Cancer Chemother Pharmacol       Date:  2003-12-05       Impact factor: 3.333

8.  Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.

Authors:  Matthias Miederer; Michael R McDevitt; George Sgouros; Kim Kramer; Nai-Kong V Cheung; David A Scheinberg
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

Review 9.  A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects.

Authors:  Scott E Strome; Edward A Sausville; Dean Mann
Journal:  Oncologist       Date:  2007-09

Review 10.  Advances in the treatment for haematological malignancies.

Authors:  Pier Paolo Piccaluga; Giovanni Martinelli; Michele Baccarani
Journal:  Expert Opin Pharmacother       Date:  2006-04       Impact factor: 3.889

View more
  21 in total

Review 1.  Personalized oncology in interventional radiology.

Authors:  Nadine Abi-Jaoudeh; Austin G Duffy; Tim F Greten; Elise C Kohn; Timothy W I Clark; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2013-08       Impact factor: 3.464

2.  Research perspectives: gold nanoparticles in cancer theranostics.

Authors:  Junjie Li; Sanjay Gupta; Chun Li
Journal:  Quant Imaging Med Surg       Date:  2013-12

3.  Diverse responses to vascular disrupting agent combretastatin a4 phosphate: a comparative study in rats with hepatic and subcutaneous tumor allografts using MRI biomarkers, microangiography, and histopathology.

Authors:  Junjie Li; Feng Chen; Yuanbo Feng; Marlein Miranda Cona; Jie Yu; Alfons Verbruggen; Jian Zhang; Raymond Oyen; Yicheng Ni
Journal:  Transl Oncol       Date:  2013-02-01       Impact factor: 4.243

4.  Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo.

Authors:  Nan Yao; Ke Ren; Cuihua Jiang; Meng Gao; Dejian Huang; Xiao Lu; Bin Lou; Fei Peng; Aizhen Yang; Xiaoning Wang; Yicheng Ni; Jian Zhang
Journal:  Tumour Biol       Date:  2015-05-31

5.  A single-dose toxicity study on non-radioactive iodinated hypericin for a targeted anticancer therapy in mice.

Authors:  Jun-jie Li; Marlein Miranda Cona; Yuan-bo Feng; Feng Chen; Guo-zhi Zhang; Xue-bin Fu; Uwe Himmelreich; Raymond Oyen; Alfons Verbruggen; Yi-cheng Ni
Journal:  Acta Pharmacol Sin       Date:  2012-10-29       Impact factor: 6.150

Review 6.  Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.

Authors:  Mei Liu; Zhiyang Li; Jingjing Yang; Yanyun Jiang; Zhongsi Chen; Zeeshan Ali; Nongyue He; Zhifei Wang
Journal:  Cell Prolif       Date:  2016-06-16       Impact factor: 6.831

7.  Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors.

Authors:  Casimiro Luca Gigliotti; Benedetta Ferrara; Sergio Occhipinti; Elena Boggio; Giuseppina Barrera; Stefania Pizzimenti; Mirella Giovarelli; Roberto Fantozzi; Annalisa Chiocchetti; Monica Argenziano; Nausicaa Clemente; Francesco Trotta; Caterina Marchiò; Laura Annaratone; Renzo Boldorini; Umberto Dianzani; Roberta Cavalli; Chiara Dianzani
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

8.  Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications.

Authors:  Junjie Li; Raymond Oyen; Alfons Verbruggen; Yicheng Ni
Journal:  J Cancer       Date:  2013-01-22       Impact factor: 4.207

9.  Exploring theranostic potentials of radioiodinated hypericin in rodent necrosis models.

Authors:  Junjie Li; Marlein Miranda Cona; Feng Chen; Yuanbo Feng; Lin Zhou; Jie Yu; Johan Nuyts; Peter de Witte; Jian Zhang; Uwe Himmelreich; Alfons Verbruggen; Yicheng Ni
Journal:  Theranostics       Date:  2012-10-18       Impact factor: 11.556

10.  Sequential systemic administrations of combretastatin A4 Phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts.

Authors:  Junjie Li; Marlein Miranda Cona; Feng Chen; Yuanbo Feng; Lin Zhou; Guozhi Zhang; Johan Nuyts; Peter de Witte; Jian Zhang; Jie Yu; Raymond Oyen; Alfons Verbruggen; Yicheng Ni
Journal:  Theranostics       Date:  2013-02-13       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.